Bevyxxa and Fedratinib

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, other anticoagulants, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during betrixaban therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis. MANAGEMENT: Caution is recommended if betrixaban must be used with other agents that alter hemostasis. Some authorities consider concomitant treatment with other anticoagulants to be relatively contraindicated except under special circumstances such as switching oral anticoagulant therapy, or when unfractionated heparin is used at doses required to maintain a patent central venous or arterial catheter. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. References "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals, South San Francisco, CA.

MONITOR CLOSELY: Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, other anticoagulants, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during betrixaban therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis.

MANAGEMENT: Caution is recommended if betrixaban must be used with other agents that alter hemostasis. Some authorities consider concomitant treatment with other anticoagulants to be relatively contraindicated except under special circumstances such as switching oral anticoagulant therapy, or when unfractionated heparin is used at doses required to maintain a patent central venous or arterial catheter. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.

Bevyxxa

Generic Name: betrixaban

Brand name: Bevyxxa

Synonyms: n.a.

What is Bevyxxa?

Fedratinib

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Fedratinib?